Supreme PLC has announced that it remains on track to meet the market views for adjusted Ebitda for the fiscal year 2024. The London-listed consumer-goods distributor has provided a consensus of £25.6 million ($32 million) for adjusted earnings before interest, taxes, depreciation, and amortization for the year ending March 31. This shows an increase from £19.4 million in fiscal 2023.

Review of Impact of Proposed Ban on Disposable Vape Devices

Responding to press reports regarding a possible ban on disposable vape devices in the U.K. to combat underage vaping, Supreme PLC has stated that it will conduct a comprehensive review of the impact of any proposed changes over the medium to long term. The company will await further clarity before making any decisions.

Supreme PLC expects that if a ban on disposables is implemented, most of its current consumers will transition to alternative forms of vaping. However, it emphasizes that no new legislation will be put into effect until after a formal government consultation.

Positive Market Response

Supreme PLC's shares have seen a positive market response, with an increase of 2.1% to 96.0 pence as of 0739 GMT.

Hamburg Port Operator Receives Takeover Offer

Sutton Harbour Group Reports Strong Summer Performance

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Robinhood Launches Commission-Free Crypto Trading App in EU
News

Robinhood Launches Commission-Free Crypto Trading App in EU

Robinhood expands internationally with a commission-free crypto trading app in the EU, allowing customers to trade 25+ c...

Thai Shares Show Modest Gain
News

Thai Shares Show Modest Gain

The Thai stock market showed a modest gain, with top gainers and losers in the technology sector. Updates on other South...

U.K. Stock Market Report
News

U.K. Stock Market Report

The U.K. stock market finished flat, with the FTSE 100 Index closing at 7,417.76. Get insights on the day's top gainers...

Positive Results and Completion of Phase 3 Trial for Brilaroxazine in Schizophrenia Patients
News

Positive Results and Completion of Phase 3 Trial for Brilaroxazine in Schizophrenia Patients

Reviva Pharmaceuticals sees stock surge after positive results and completion of Phase 3 trial for Brilaroxazine in trea...